BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34844036)

  • 21. Synthesis and biological evaluation of novel steroidal 5α,8α-epidioxyandrost-6-ene-3β-ol-17-(O-phenylacetamide)oxime derivatives as potential anticancer agents.
    Bu M; Cao T; Li H; Guo M; Yang BB; Zeng C; Zhou Y; Zhang N; Hu L
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3856-3861. PubMed ID: 28666736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
    Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
    Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance.
    Zha GF; Qin HL; Youssif BGM; Amjad MW; Raja MAG; Abdelazeem AH; Bukhari SNA
    Eur J Med Chem; 2017 Jul; 135():34-48. PubMed ID: 28431353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
    Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
    Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
    Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
    Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells.
    Xiong B; Chen S; Zhu P; Huang M; Gao W; Zhu R; Qian J; Peng Y; Zhang Y; Dai H; Ling Y
    Med Chem; 2019; 15(7):743-754. PubMed ID: 30147012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment-based identification of Hsp90 inhibitors.
    Barker JJ; Barker O; Boggio R; Chauhan V; Cheng RK; Corden V; Courtney SM; Edwards N; Falque VM; Fusar F; Gardiner M; Hamelin EM; Hesterkamp T; Ichihara O; Jones RS; Mather O; Mercurio C; Minucci S; Montalbetti CA; Müller A; Patel D; Phillips BG; Varasi M; Whittaker M; Winkler D; Yarnold CJ
    ChemMedChem; 2009 Jun; 4(6):963-6. PubMed ID: 19301319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alkaloid derivative ION-31a inhibits breast cancer metastasis and angiogenesis by targeting HSP90α.
    Ni TW; Duan XC; Wang M; Jia MQ; Chen Y; Yu Y; Qin N; Duan HQ
    Bioorg Chem; 2021 Oct; 115():105201. PubMed ID: 34329994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
    Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
    Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
    Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
    Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitrogen-containing ecdysteroid derivatives vs. multi-drug resistance in cancer: Preparation and antitumor activity of oximes, oxime ethers and a lactam.
    Vágvölgyi M; Martins A; Kulmány Á; Zupkó I; Gáti T; Simon A; Tóth G; Hunyadi A
    Eur J Med Chem; 2018 Jan; 144():730-739. PubMed ID: 29291440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
    Byrd KM; Kent CN; Blagg BSJ
    ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
    Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereospecific antitumor activity of radicicol oxime derivatives.
    Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
    Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
    Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
    Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
    Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.